Lipids & metabolic liver disease
Glycated haemoglobin is a major predictor of disease severity in patients with non-alcoholic fatty liver disease (NAFLD)
Authors' conclusion
HbA1c is highly informative in predicting NAFLD severity and contributes more than BMI. Assessments of HbA1c must be a fundamental part of the holistic assessment of patients with NAFLD and, alongside age, can be used to identify patients with highest risk of advanced disease.
Study context
- Population
- Patients with liver biopsy staged NAFLD, with and without T2D857 patients with biopsy-staged NAFLD
- Participants
- 687 / 170 / 421
- Comparison
- HbA1c vs NAFLD histological severity
- Discoveryn = 687
- Validationn = 170
- Paired biopsiesn = 421
- Outcome
- Relationship between HbA1c and NAFLD severity (severe steatosis, NASH, advanced fibrosis)
Methodological detailsliver biopsy staged, generalized-linear models and binomial regression
- Liver biopsy staged
- Generalized-linear models and binomial regression
Performance
As reported in the abstract
Risk of severe steatosis, NASH and advanced fibrosis
- In the discovery cohort, risk of severe steatosis, non-alcoholic steatohepatitis (NASH) and advanced fibrosis correlated positively with HbA1c, after adjustment for obesity and age
- Findings endorsed in a separate validation cohort
- Adjusted for obesity and age
Further findings
Predictive modelling with HbA1c and age vs Fib-4
- Predictive modelling using HbA1c and age was non-inferior to Fib-4; allowed HbA1c, age and BMI adjusted risk charts
Change after intervention (paired biopsies)
- Reduction in HbA1c associated with improvements in steatosis and NASH after adjustment for weight change and treatment
- Fibrosis change only associated with weight change and treatment
Original publication
Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD. Diabetes Res Clin Pract. Published 13 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →